Glaukos has entered into a collaboration and marketing agreement with Radius XR, seeing Glaukos become the exclusive sales agent to market, promote and solicit orders for the Radius XR wearable patient engagement and diagnostic system within the US.
As part of the deal, Radius will continue to lead development and commercialisation efforts for Radius XR.
Glaukos, an ophthalmic medical technology and pharmaceutical company developing novel therapies for glaucoma, corneal disorders and retinal diseases, announced the agreement in mid-July 2023.
The deal centres on the Radius XR platform, described as a novel portable vision diagnostic and patient engagement system designed for more efficient detection of eye disease and better management and treatment of sight-threatening conditions.
It combines medical-grade diagnostics, business management tools and patient education resources within a wearable spatial computing device. The hardware and software system provides is designed to allow medical professionals to diagnose patients accurately, enhance patient engagement and reduce staff workload.
The system also enables patients to perform self-guided vision tests with minimal supervision, aiding in eyecare practices’ flow, efficiency and patient experience.
“Today marks a notable milestone for Radius and more importantly, for patients suffering from chronic eye diseases,” said Radius CEO Mr Ammad Khan. “Glaukos is highly trusted and respected by vision care providers, and this collaboration will provide us with the necessary resources to expedite product development, optimise benefits for eyecare providers and enhance the overall quality of care and access for patients.
“Through this partnership, Radius will benefit from Glaukos’ market-building expertise, leveraging its well-established sales team with extensive clinical knowledge and technical insight to commercialise and drive greater patient access for the Radius XR technology.”
Glaukos chairman and CEO Mr Thomas Burns, said the Radius XR platform is a novel technology that can help drive more efficient and improved diagnosis for patients suffering from chronic eye diseases, while also creating efficiency and growth opportunities for eye care practices.
“This collaboration aligns with our mission to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases,” he said.
More reading
Glaukos submits FDA application for iDose TR glaucoma implant
Glaukos announces FDA clearance for iStent infinite
Glaukos commences trials for its third-generation keratoconus therapy
